CTT PHARMACEUTICAL HOLDINGS, INC.

S-1/A amended

6,250,000 shares

CTT Pharmaceutical Holdings, Inc. is conducting an IPO involving the resale of up to 6,250,000 shares of common stock by RH2 Equity Partners under an Equity Line of Credit Agreement (ELOC). The company, a development-stage entity focused on fast-dissolving drug delivery systems, seeks to raise up to $10 million via the ELOC for working capital and strategic purposes. The filing highlights risks related to its early-stage operations, lack of revenue, and reliance on a single product platform.

S-1 filed

6,250,000 shares

CTT Pharmaceutical Holdings, Inc. is a development-stage company focused on developing fast-dissolving oral drug delivery systems using advanced thin dissolvable strips. The company is registering 6,250,000 shares of common stock for resale by RH2 Equity Partners, a selling stockholder, under a Committed Equity Financing Agreement (ELOC). While the company will not receive proceeds from the resale, it may receive up to $3 million in gross proceeds from future sales under the ELOC, intended for working capital and manufacturing expansion. The offering highlights risks related to its early-stage development, reliance on patents, and market adoption of its technology.